agͼ

ԴӰϷаߣ 

Ҹ㽲طﲻǺҲ̹ǹ˽͵еˬʽæԼѳȥɿ𽲶þ θյ׿ܱӴ

ýֵġְλ

ôõʵҲȽɢҪĸطѡԼ۱Ȼ˻ᵽǺǺܱвõӹŰʽõ̩ʽЧȫ۸Ҳһ㶼ʵҪǵһοDz

Ƽ˽õ

ͼƬ

áɹ⿴ÿϸصѽ׷ˬȥһЩСڵĵطñȿ·ܵСͷЩȻЧʦַרҵҲƽúرʺɿ۸һǺһԼ۱ȸ

ʵСʿ·СǰԤԼʱ˶ʱȥδػ˿

ôѡŲȿ

ʵڻõǼѡ˿ܻȿҵĽȿDzǽྻֱӰǿʦһﶼЩ֤߿ڱǷ˼۸̫ƵҪһǮһֻ


ͼƬ

ǾҪѡûȿ 

ô㽲һȥѡǺϵĵȵҪ׷Լ۱Կ·Сǵǰ绰ѡʱЧֻ۸

, Ǻ, ·Ƽ, Чָ, ɿй

İİܵſ

In the field of gastrointestinal cancers,in addition to the approved esophageal squamous cell carcinoma(ESCC)indication,serplulimab is the First drug to receive Breakthrough Therapy Designation from the National Medical Products Administration(NMPA)Center for Drug Evaluation(CDE).As the worlds First perioperative regimen for gastric cancer to replace adjuvant chemotherapy with immunotherapy monotherapy,its New Drug Application(NDA)has been accepted by the CDE and granted Priority Review.Besides,an International,multicenter Phase3trial(ASTRUM-015)of serplulimab in combination with bevacizumab and chemotherapy as First-line therapy for metastatic colorectal cancer(mCRC)has completed patient enrollment,potentially addressing the clinical gap in First-line immunotherapy for non-MSI-H mCRC.At this conference,positive results of serplulimab from two investigator-initiated trials(IITs)for neoadjuvant therapy in locally advanced colon/rectal cancer were released.The data indicate that serplulimab in neoadjuvant therapy is expected to improve the chances of radical surgery and long-term survival rates for patients with locally advanced high-risk colon cancer,while also showing potential to provide a radiation-free treatment regimen for patients with locally advanced rectal cancer.

һ

Сÿ꿪һ£ǧĹʦ͹Ŷ2020Ѿ佱7Ѿ7500Ԫ

һ֡

˳糵Ӧһ˳·ϳΪڳõĻ˳·˳·֮ͬɺϳ˺̯Ҫöȵ˶Լ˳糵˽ҳͨƽ̨гϢټ·ͬ˺ϳ˵ΪԼ˳糵һڳĿġʻ·Ƶʡöȷ̯ϷʱӦ϶Լ˳糵ӪΣ

վͼ